Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2014 | 06-2014 | 03-2014 | 12-2013 | 09-2013 | |
| Sales | 3,960,322 | 3,975,410 | 3,737,009 | 3,956,654 | 3,642,754 |
| Cost of Goods | 609,828 | 674,730 | 636,704 | 621,369 | 626,040 |
| Gross Profit | 3,350,494 | 3,300,680 | 3,100,305 | 3,335,285 | 3,016,714 |
| Operating Expenses | 1,826,040 | 1,696,285 | 1,625,347 | 1,989,453 | 1,597,375 |
| Operating Income | 1,525,282 | 1,605,125 | 1,475,662 | 1,346,202 | 1,419,379 |
| Interest Expense | 78,498 | 25,732 | 58,417 | 31,215 | 19,714 |
| Other Income | 58,028 | 72,785 | 107,649 | 109,505 | 74,237 |
| Pre-tax Income | 1,504,812 | 1,652,178 | 1,524,894 | 1,424,492 | 1,473,902 |
| Income Tax | 347,812 | 366,681 | 338,559 | 317,735 | 334,598 |
| Net Income Continuous | 1,157,000 | 1,285,497 | 1,186,335 | 1,106,757 | 1,139,304 |
| Net Income | $1,157,000 | $1,285,497 | $1,186,335 | $1,106,757 | $1,139,304 |
| EPS Basic Total Ops | 0.22 | 0.24 | 0.22 | 0.21 | 0.21 |
| EPS Basic Continuous Ops | 0.22 | 0.24 | 0.22 | 0.21 | 0.21 |
| EPS Diluted Total Ops | 0.22 | 0.24 | 0.22 | 0.21 | 0.21 |
| EPS Diluted Continuous Ops | 0.22 | 0.24 | 0.22 | 0.21 | 0.21 |
| EBITDA(a) | $1,525,282 | $1,605,125 | $1,475,662 | $1,346,201 | $1,419,379 |